300436.SZ
广生堂
SZSE · Healthcare · C 制造业 · CN
CNY 89.66
−3.72%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−118.7x
Market Cap
CNY 14.28B
MomentumView details →
1D Return
−3.72%
YTD Return
+0.67%
RSI (14)
43.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−118.7x
Market Cap
CNY 14.28B
RSI (14)
43.1
MomentumView details →
1D Return
−3.72%
YTD Return
+0.67%
Similar companies
Latest newsMore news →
GST-Peak-Triple, a triple all-oral regimen for chronic hepatitis B developed by Fujian Gsoon Zhonglin Biotech, a subsidiary of Gsoon Group, completed first patient enrollment and dosing in a Phase II clinical trial.10h agoShareholder Zhangzhou Yuanshan Big Health Industry Investment Fund Partnership (Limited Partnership) saw its stake in Ganshantang passively diluted from 5.02% to 4.76% after not participating in the new share issuance, falling below the 5% threshold.3d agoGanshantang issued 8.7594 million new A-shares to specific investors, increasing total share capital from 159 million to 168 million shares, with the new shares listing on the Shenzhen Stock Exchange on September 3, 2026.3d ago